Close
Smartlab Europe
Achema middle east

Lupin Announces Final FDA Approval of Generic Hyzaar® and Cozaar

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...
- Advertisement -

Pharma Major, Lupin Limited announced that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has been granted final approval for the company’s generic versions of Merck’s antihypertensive agents *Hyzaar® (hydrochlorothiazide; losartan potassium) and *Cozaar® (losartan potassium) by the U.S. Food and Drug Administration.

The brand products had combined annual sales of approximately $1.6 billion in the United States, based on IMS sales data for the 12 months ended June 2010.

Latest stories

Related stories

Therapeutic Frontiers in Malignant Mesothelioma Management

Malignant mesothelioma is one of oncology’s most challenging diagnoses....

CRO Clinical Trials: Structure and Purpose in Modern Research

Clinical trials require carefully organized processes to ensure that...

AstraZeneca-Modella AI Acquisition to Speed Oncology R&D

AstraZeneca has agreed to acquire Boston-based Modella AI as...

Novartis, SciNeuro Brain Shuttle Deal Expands Neuroscience

Novartis has entered into a licensing agreement with SciNeuro...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »